Biogen still on hold by Jefferies

Jefferies & Co., Inc. analyst Adam Walsh maintained Biogen Idec Inc. at hold as it awaits more visibility on Tysabri. According to the analyst, it is still too early to read intro the Tysabri trajectory, as factors gating uptake - educating/training physicians and administration sites on the Touch program, patient enrollment and reimbursement - are still in the process of being addressed. Shares of the Cambridge, Mass.-based pharmaceutical company dropped $0.39, or 0.88%, to $44.02 on volume of 2,568,967 shares versus the three-month running average of 2,774,510 shares. (Nasdaq: BIIB)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.